Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.

Dong, Ziwei; Ye, Xiaofei; Chen, Chenxin; Wang, Rui; Liu, Dongxu; Xu, Xiao; Zhou, Xiang; He, Jia

Dong, Ziwei; Ye, Xiaofei; Chen, Chenxin; Wang, Rui; Liu, Dongxu; Xu, Xiao; Zhou, Xiang; He, Jia.

Afiliação

Dong Z; School of Medicine, Tongji University Shanghai, China.
Ye X; Department of Health Statistics, Naval Medical University, Shanghai, China.
Chen C; Department of Health Statistics, Naval Medical University, Shanghai, China.
Wang R; Department of Health Statistics, Naval Medical University, Shanghai, China.
Liu D; School of Medicine, Tongji University Shanghai, China.
Xu X; School of Medicine, Tongji University Shanghai, China.
Zhou X; School of Medicine, Tongji University Shanghai, China.
He J; School of Medicine, Tongji University Shanghai, China.

Br J Clin Pharmacol ; 88(9): 4180-4190, 2022 09.

Article em En | MEDLINE | ID: mdl-35466415

Assuntos

Inibidores de Janus Quinases; Embolia Pulmonar; Tromboembolia; Sistemas de Notificação de Reações Adversas a Medicamentos; Humanos; Inibidores de Janus Quinases/efeitos adversos; Preparações Farmacêuticas; Farmacovigilância; Embolia Pulmonar/induzido quimicamente; Embolia Pulmonar/epidemiologia; Tromboembolia/induzido quimicamente; Tromboembolia/epidemiologia; Estados Unidos/epidemiologia; United States Food and Drug Administration

Palavras-chave

FAERS; JAK inhibitors; disproportionality analysis; pharmacovigilance study; spontaneous reporting system; thromboembolic events

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Embolia Pulmonar / Tromboembolia / Inibidores de Janus Quinases Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google